Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Barry J. Simon Insider Profile
4 Followers
Barry J. Simon , Director at ImmunityBio, holds 3.12M shares in ImmunityBio (Ticker: IBRX), holds ― shares in Cue Biopharma (Ticker: CUE), holds ― shares in Viracta Therapeutics (Ticker: VIRX).
Barry J. Simon has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Barry J. Simon holds in companies
Most Profitable Insider Trade
The most profitable trade made by Barry J. Simon
Barry J. Simon 's Trading History
ImmunityBio
Feb 02, 2024
Director
Uninformative Buy
117.96K
$19.74M
Cue Biopharma
―
Director
―
―
Viracta Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Barry J. Simon 's performance on stock
You May Also Like
Barry J. Simon insider profile FAQ
What is the percentage of profitable transactions made by Barry J. Simon ?
The percentage of profitable transactions made by Barry J. Simon is ―.
What is the average return per transaction made by Barry J. Simon ?
The average return per transaction made by Barry J. Simon is ―.
What stocks does Barry J. Simon hold?
Barry J. Simon holds: IBRX, CUE, VIRX stocks.
What was Barry J. Simon ’s latest transaction?
Barry J. Simon latest transaction was an Uninformative Buy of $117.96K.
What was Barry J. Simon 's most profitable transaction?
Barry J. Simon ’s most profitable transaction was an Informative Sell of IBRX stock on May 25, 2021. The return on the trade was 77.70%.
What is Barry J. Simon 's role in ImmunityBio?
Barry J. Simon 's role in ImmunityBio is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.